GAD Parkinson’s disease gene therapy has met its primary endpoint. The sham-controlled bridging study evaluated the company's ...

MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...

According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local ...

A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...

Advancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for ...

The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...

Researchers have developed a revolutionary magnetogenetics technology that can control brain circuits non-invasively using ...

Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, ...

MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...

MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...

An innovative genetic treatment for Gaucher disease has shown promise in mouse models, increasing lifespan and preserving ...

Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical ...